For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Tramadol hydrochloride - Pain (non-malignant)
PAD Profile : Tramadol hydrochloride - Pain (non-malignant)
Traffic Light Status
Status 1 of 1.
- Capsules
- Modified release capsules
- Modified release tablets
Guidelines
No guidelines returned.
Other Drugs
- Tapentadol hydrochloride
- Oxycodone
- Co-codamol (Codeine phosphate/paracetamol)
- Tramadol hydrochloride
- Codeine phosphate
- Buprenorphine
- Morphine sulfate
- Pregabalin
- Gabapentin
- Meptazinol hydrochloride
- Co-dydramol (Dihydrocodeine/paracetamol)
Other Indications
Additional Documents
Committee Recommendations
It is recommended that tramadol modified release preparations are prescribed by BRAND - see UKMI Branded Prescribing Recommendations document below. The locally preferred brand for modified-release, TWICE DAILY dosing is Marol® Marol® is available across all of the twice-daily dose ranges, already represents the most commonly prescribed tramadol brand locally and nationally and remains one of the most cost-effective tramadol MR choices. Patients currently receiving generically written prescriptions should be reviewed with a view to change the prescribing to a cost-effective brand.
A stepped approach to pain management is recommended. Paracetamol is considered a 1st line option for the treatment of pain. A trial of tramadol (patient agreement) may be considered if maximum tolerated doses of codeine /dihydrocodeine are ineffective. Consider whether all measures have been taken to control side effects. Please refer to the guidelines attached:
Ensure a patient agreement is completed by the patient (see below) prior to a trial of tramadol.
PLEASE NOTE:
- Standard/Immediate release capsules should be prescribed GENERICALLY
- Modified release tablets should be prescribed by BRAND with Marol® being locally preferred (See below)